These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 35152886)

  • 1. Pharmacodynamic evaluation and safety assessment of treatment with antibodies to serum amyloid P component in patients with cardiac amyloidosis: an open-label Phase 2 study and an adjunctive immuno-PET imaging study.
    Wechalekar A; Antoni G; Al Azzam W; Bergström M; Biswas S; Chen C; Cheriyan J; Cleveland M; Cookson L; Galette P; Janiczek RL; Kwong RY; Lukas MA; Millns H; Richards D; Schneider I; Solomon SD; Sörensen J; Storey J; Thompson D; van Dongen G; Vugts DJ; Wall A; Wikström G; Falk RH
    BMC Cardiovasc Disord; 2022 Feb; 22(1):49. PubMed ID: 35152886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An observational, non-interventional study for the follow-up of patients with amyloidosis who received miridesap followed by dezamizumab in a phase 1 study.
    Richards D; Millns H; Cookson L; Lukas MA
    Orphanet J Rare Dis; 2022 Jul; 17(1):259. PubMed ID: 35810311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component.
    Richards DB; Cookson LM; Berges AC; Barton SV; Lane T; Ritter JM; Fontana M; Moon JC; Pinzani M; Gillmore JD; Hawkins PN; Pepys MB
    N Engl J Med; 2015 Sep; 373(12):1106-14. PubMed ID: 26176329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis.
    Richards DB; Cookson LM; Barton SV; Liefaard L; Lane T; Hutt DF; Ritter JM; Fontana M; Moon JC; Gillmore JD; Wechalekar A; Hawkins PN; Pepys MB
    Sci Transl Med; 2018 Jan; 10(422):. PubMed ID: 29298867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel methods to determine complement activation in human serum induced by the complex of Dezamizumab and serum amyloid P.
    Ma J; Liu Q; White JR
    J Biol Chem; 2021 Oct; 297(4):101136. PubMed ID: 34461096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Intravenous Dose of Miridesap in Healthy Japanese Subjects.
    Ino H; Doi Y; Liefaard L; Cookson L; Chen C; Itoh H; Igarashi H; Nakano A
    Clin Pharmacol Drug Dev; 2019 Jul; 8(5):612-618. PubMed ID: 30556959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiac Amyloid Detection by PET/CT Imaging of Iodine (
    Wall JS; Martin EB; Lands R; Ramchandren R; Stuckey A; Heidel RE; Whittle B; Powell D; Richey T; Williams AD; Foster JS; Guthrie S; Kennel SJ
    JACC Cardiovasc Imaging; 2023 Nov; 16(11):1433-1448. PubMed ID: 37940323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Pentraxins 1975-2018: Serendipity, Diagnostics and Drugs.
    Pepys MB
    Front Immunol; 2018; 9():2382. PubMed ID: 30459761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pittsburgh B Compound Positron Emission Tomography in Patients With AL Cardiac Amyloidosis.
    Lee SP; Suh HY; Park S; Oh S; Kwak SG; Kim HM; Koh Y; Park JB; Kim HK; Cho HJ; Kim YJ; Kim I; Yoon SS; Seo JW; Paeng JC; Sohn DW
    J Am Coll Cardiol; 2020 Feb; 75(4):380-390. PubMed ID: 32000949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advancing
    Wuensche TE; Stergiou N; Mes I; Verlaan M; Schreurs M; Kooijman EJM; Janssen B; Windhorst AD; Jensen A; Asuni AA; Bang-Andersen B; Beaino W; Dongen GAMS; Vugts DJ
    Theranostics; 2022; 12(16):7067-7079. PubMed ID: 36276653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 11C-Pittsburgh B PET imaging in cardiac amyloidosis.
    Lee SP; Lee ES; Choi H; Im HJ; Koh Y; Lee MH; Kwon JH; Paeng JC; Kim HK; Cheon GJ; Kim YJ; Kim I; Yoon SS; Seo JW; Sohn DW
    JACC Cardiovasc Imaging; 2015 Jan; 8(1):50-59. PubMed ID: 25499132
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Jauw YWS; O'Donoghue JA; Zijlstra JM; Hoekstra OS; Menke-van der Houven van Oordt CW; Morschhauser F; Carrasquillo JA; Zweegman S; Pandit-Taskar N; Lammertsma AA; van Dongen GAMS; Boellaard R; Weber WA; Huisman MC
    J Nucl Med; 2019 Dec; 60(12):1825-1832. PubMed ID: 31147401
    [No Abstract]   [Full Text] [Related]  

  • 13. First in Human Evaluation and Dosimetry Calculations for Peptide
    Wall JS; Martin EB; Endsley A; Stuckey AC; Williams AD; Powell D; Whittle B; Hall S; Lambeth TR; Julian RR; Stabin M; Lands RH; Kennel SJ
    Mol Imaging Biol; 2022 Jun; 24(3):479-488. PubMed ID: 34786667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis.
    Gillmore JD; Tennent GA; Hutchinson WL; Gallimore JR; Lachmann HJ; Goodman HJ; Offer M; Millar DJ; Petrie A; Hawkins PN; Pepys MB
    Br J Haematol; 2010 Mar; 148(5):760-7. PubMed ID: 20064157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extracardiac
    Wagner T; Page J; Burniston M; Skillen A; Ross JC; Manwani R; McCool D; Hawkins PN; Wechalekar AD
    Eur J Nucl Med Mol Imaging; 2018 Jul; 45(7):1129-1138. PubMed ID: 29651545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis.
    Pepys MB; Herbert J; Hutchinson WL; Tennent GA; Lachmann HJ; Gallimore JR; Lovat LB; Bartfai T; Alanine A; Hertel C; Hoffmann T; Jakob-Roetne R; Norcross RD; Kemp JA; Yamamura K; Suzuki M; Taylor GW; Murray S; Thompson D; Purvis A; Kolstoe S; Wood SP; Hawkins PN
    Nature; 2002 May; 417(6886):254-9. PubMed ID: 12015594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extracellular remodeling in patients with wild-type amyloidosis consuming epigallocatechin-3-gallate: preliminary results of T1 mapping by cardiac magnetic resonance imaging in a small single center study.
    aus dem Siepen F; Buss SJ; Andre F; Seitz S; Giannitsis E; Steen H; Katus HA; Kristen AV
    Clin Res Cardiol; 2015 Aug; 104(8):640-7. PubMed ID: 25855392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE).
    Salloway S; Honigberg LA; Cho W; Ward M; Friesenhahn M; Brunstein F; Quartino A; Clayton D; Mortensen D; Bittner T; Ho C; Rabe C; Schauer SP; Wildsmith KR; Fuji RN; Suliman S; Reiman EM; Chen K; Paul R
    Alzheimers Res Ther; 2018 Sep; 10(1):96. PubMed ID: 30231896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognosis of Light Chain Amyloidosis With Preserved LVEF: Added Value of 2D Speckle-Tracking Echocardiography to the Current Prognostic Staging System.
    Barros-Gomes S; Williams B; Nhola LF; Grogan M; Maalouf JF; Dispenzieri A; Pellikka PA; Villarraga HR
    JACC Cardiovasc Imaging; 2017 Apr; 10(4):398-407. PubMed ID: 27639764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Donanemab (LY3002813) Phase 1b Study in Alzheimer's Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging.
    Lowe SL; Duggan Evans C; Shcherbinin S; Cheng YJ; Willis BA; Gueorguieva I; Lo AC; Fleisher AS; Dage JL; Ardayfio P; Aguiar G; Ishibai M; Takaichi G; Chua L; Mullins G; Sims JR
    J Prev Alzheimers Dis; 2021; 8(4):414-424. PubMed ID: 34585215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.